Following the completion of their business combination, Kinarus Therapeutics Holding AG and its wholly owned subsidiary Curatis Group AG have started a new strategic journey. Kinarus has rebranded itself to Curatis Holding AG. Curatis has become a publicly traded company under the name Curatis Group, based in Liestal, Basel.

在完成业务合并后，Kinarus Therapeutics Holding AG及其全资子公司Curatis Group AG开始了新的战略旅程。Kinarus已更名为Curatis Holding AG。Curatis已成为一家上市公司，名称为Curatis Group，总部位于巴塞尔利斯塔尔。

As of today, CURN.SW shares are trading on the SIX Swiss Exchange..

截至今日，CURN.SW股票在瑞士六大交易所交易。。

Early this year, Curatis announced the reverse merger with Kinarus, a publicly listed specialty pharmaceutical company with a distribution and drug development business, to save it from bankruptcy. The business combination of the two companies has now been completed and new changes have been enforced.

今年年初，Curatis宣布与Kinarus反向合并，Kinarus是一家上市的专业制药公司，拥有分销和药物开发业务，以使其免于破产。两家公司的业务合并现已完成，新的变化也已实施。

Kinarus Therapeutics Holding AG has been renamed to Curatis Holding AG while Curatis is now listed on the Swiss Exchange under the name of Curatis Group (CURN.SW) with a domicile in Liestal, Basel-Landschaft. A total of CHF 4.36m in cash was raised in Q1 2024 in connection with the business combination.Marian Borovsky, Chairman of Curatis Holding AG says, 'We are very excited about this Business Combination as it allows Curatis AG to continue its successful business activities as part of a publicly listed group and adds Kinarus’ compound platform KIN001 to our promising development portfolio (...).”.

Kinarus Therapeutics Holding AG已更名为Curatis Holding AG，而Curatis现在以Curatis Group（CURN。SW）的名义在瑞士交易所上市，住所位于巴塞尔兰德沙夫特的利斯达尔。2024年第1季度，与企业合并相关的现金总额为436万瑞士法郎。Curatis Holding AG董事长玛丽安·博罗夫斯基（MarianBorovsky）表示，“我们对这次业务合并感到非常兴奋，因为它使Curatis AG能够作为上市集团的一部分继续其成功的业务活动，并将Kinarus的复合平台KIN001添加到我们有希望的发展组合中（……）。”。

With Curatis now being part of a publicly listed group and the expected increase in public visibility and credibility, the company aims to grow its speciality pharmaceuticals distribution business by expanding its product offering in Switzerland as well as geographically expanding its distribution business to large European markets such as Germany, France, the U.K., and Italy..

由于Curatis目前是一家上市集团的一部分，公众知名度和可信度有望提高，该公司旨在通过扩大其在瑞士的产品供应以及将其分销业务扩展到德国、法国、英国和意大利等大型欧洲市场来发展其特殊药品分销业务。。

Founded in 2002, Curatis is focused on the acquisition, development and commercialisation of innovative medicines for the prevention, diagnosis and treatment of rare diseases - often referred to as orphan diseases - and special care diseases. It also operates a distribution business with a sizeable and historically profitable portfolio of interesting, marketed orphan and specialty products in Switzerland and has a pipeline of four promising projects in advanced and late clinical development..

Curatis成立于2002年，专注于购买、开发和商业化创新药物，用于预防、诊断和治疗罕见疾病（通常称为孤儿疾病）和特殊护理疾病。它还经营着一家分销业务，在瑞士拥有规模庞大且历史上盈利的有趣的孤儿和专业产品组合，并在先进和晚期临床开发中拥有四个有前途的项目。。

C-PTBE-01: for the treatment of peritumoral brain edema in pediatric patients with diffuse intrinsic pontine glioma (“DIPG”) – next major development step: pivotal clinical study

C-PTBE-01：用于治疗弥漫性桥脑胶质瘤（“DIPG”）儿科患者的瘤周脑水肿-下一个主要发展步骤：关键临床研究

C-AM-01: for the prevention of severe migraine with aura ('MwA') – next major development step: clinical phase IIb study

C-AM-01：用于预防有先兆的严重偏头痛（“MwA”）–下一个主要发展步骤：临床IIb期研究

C-MOH-01: for the treatment and prevention of medication overuse headache (“MOH”) – next major development step: clinical phase IIb study

C-MOH-01：用于治疗和预防药物过度使用头痛（“MOH”）–下一个主要发展步骤：临床IIb期研究

KIN001: for the treatment of rare inflammatory and fibrotic diseases (e.g. idiopathic pulmonary fibrosis (“IPF”)) – next major development step: clinical proof-of-concept.

KIN001：用于治疗罕见的炎症和纤维化疾病（例如特发性肺纤维化（“IPF”））–下一个主要发展步骤：临床概念验证。

KIN001, developed by Kinarus, is a proprietary compound with potential in inflammatory and fibrotic diseases - a significant new element in the Group's pipeline. The Curatis Group intends to explore the potential of KIN001 in ultra-orphan inflammatory and fibrotic diseases and to pursue its own drug development for the identified ultra-orphan indications.

Kinarus开发的KIN001是一种专有化合物，具有治疗炎症和纤维化疾病的潜力，是该集团管道中的重要新元素。Curatis集团打算探索KIN001在超孤儿炎症和纤维化疾病中的潜力，并针对已确定的超孤儿适应症进行自己的药物开发。

Additionally, Curatis Group also has exclusive distribution rights in Switzerland for more than 30 different drugs developed by third party pharmaceutical companies...

此外，Curatis Group还在瑞士拥有由第三方制药公司开发的30多种不同药物的独家经销权。。。

(Press release / SR/ RAN)

（新闻稿/SR/RAN）

0Comments

0注意事项

Back to all news

返回所有新闻

Please login

请登录

or sign up

或注册

to comment.

发表评论。

Commenting guidelines

评论指南

Send

发送